TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Korean~* Type 2 diabetes mellitus~* No prior history of diabetic ketoacidosis~* HbA1c between 7.5-10.0%~Exclusion Criteria:~* Type 1 diabetes mellitus~* Gestational diabetes mellitus~* Secondary diabetes mellitus~* Severe hyperglycemia with symptoms~* Severe chronic diabetic complications (PDR,s-Cr\>1.3mg/dL)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* Laboring patients who undergo a cesarean section~Exclusion Criteria:~* Placenta/Uterine Abnormalities~* Chronic Hypertension, Gestational Hypertension, Preeclampsia~* HIV/AIDS on protease inhibitors~* History of Coronary Artery Disease~* History of Hypersensitivity to Methylergonovine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Methylergonovine 0.2 mg (Type: EXPERIMENTAL): Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement~Exclusion Criteria:~* Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin~* Severe osteoarthritis of the knee~* Inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders~* Prior knee surgery (within 6 months), excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- MACI (Type: EXPERIMENTAL): autologous cultured chondrocytes on porcine collagen membrane
- Microfracture (Type: ACTIVE_COMPARATOR): Microfracture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia in first or subsequent complete remission (de-novo or secondary AML)~* Acute lymphoblastic leukemia in first or subsequent complete remission~* Patient's age: 18 - 65 years~* Myeloablative standard conditioning~* HLA-identical sibling (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1)~* No major organ dysfunctions~* Patient's written consent~Exclusion Criteria:~* No complete remission at time of randomization~* Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as~  * Total bilirubin, SGPT or SGOT 5 times upper the normal level~ * left ventricular ejection fraction \<30%~ * Creatinine clearance \<30 ml/min~ * DLCO \<35% and/or receiving supplementary continuous oxygen~* Positive serology for HIV~* Pregnant or lactating women~* Serious psychiatric or psychological disorders~* Progressive invasive fungal infection at time of registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
- B (Type: OTHER): Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Women 18 to 24 years of age who agree to participate by signing an informed consent form prior to recruitment.~  * Girls 9 and 10 years of age whose father/mother/guardian signs the informed consent form to participate in the study.~Exclusion Criteria:~* • Prior administration of an anti-HPV vaccine~  * Pregnant women or women planning to get pregnant in the next 8 months.~ * Auto-immune diseases~ * Women with a history of Guillain Barré syndrome.~ * Prior administration of immunoglobulins and/or any blood product in the past 6 months before the study's first vaccine dose.

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- Tetravalent Vaccine (Type: ACTIVE_COMPARATOR): * Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~* Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~* Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination
- Bivalent Vaccine (Type: ACTIVE_COMPARATOR): * Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~* Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~* Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~* Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~* Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 75 years, inclusive~* Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception~* Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization~* Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS~* A colonoscopy based on AGA guidelines; every 10 years at ≥50 years old~Exclusion Criteria:~* Functional diarrhea as defined by Rome III criteria~* IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening; including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction or carcinoid syndrome.~* Potential CNS cause of constipation (e.g., Parkinson's disease, spinal cord injury, or multiple sclerosis)~* Subject has a history or current evidence of laxative abuse (in the clinical judgment of physician)~* Hepatic dysfunction (ALT \[SGPT\] or AST \[SGOT\] \>2.5 times the upper limit of normal) or renal impairment (serum creatinine \>2 mg/dL)~* Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year~* Any surgery on the stomach, small intestine or colon, excluding appendectomy and cholecystectomy (unless within 60 days of screening visit)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 50mg BID (Type: EXPERIMENTAL): Tenapanor, 50mg BID (100mg total)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study~* Normal electrocardiogram (ECG) at Screening~Exclusion Criteria:~* Clinically significant health concerns~* Regular use of alcohol within one month prior to Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study~* Recent use of illicit drugs~* Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)~NOTE: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- ARO-ANG3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 and Bone Loss in Women With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45 years~* AN defined by DSM-IV diagnostic criteria, including weight less than 85% of ideal body weight (restricting or binge/purge type, BMI 15-17.5) OR meet criteria for sub-threshold AN, i.e., all DSM-IV criteria except that patients can have a BMI of \<18.5 kg/m2 with or without amenorrhea~* Oral contraceptive use prior to enrollment~* BMD T score \< -1.0~* Normal FSH and TSH or free T4~* Normal serum 25-OH vitamin D (\>20 ng/mL) and calcium levels~* Ongoing care from a primary care provider~* Agree to use barrier contraception~Exclusion Criteria:~* Any subject with contraindications to risedronate~* Any subject with binge-purge subtype of anorexia nervosa who vomits regularly as their form of purging (vs. those who use laxatives or diuretics) and who have significant periodontal disease, tooth erosion or an invasive dental or periodontal procedure within the previous three months.~* Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure~* Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives. Bisphosphonates must have been discontinued for at least one year before participation~* Serum potassium \<3.0 meq/L~* Serum ALT \>3 times upper limit of normal~* eGFR of less than 30 ml/min~* Pregnant and/or breastfeeding~* Diabetes mellitus~* Active substance abuse, including alcohol~* History of malignancy~* Atraumatic fracture within the prior year

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- rhIGF-1 followed by Risedronate (Type: ACTIVE_COMPARATOR): Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
- Risedronate (Type: ACTIVE_COMPARATOR): Risedronate 35mg PO once weekly for 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants from 12 months of age to 15 months of age.~2. Consent form signed by both parents or by the legal representative(s), properly informed about the study,~3. Parent(s) able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine,~2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster,~3. Any known recent (≤30 days) exposure to measles, mumps or rubella,~4. Any known recent (≤30 days) exposure to varicella or zoster involving:~5. Any recent (≤3 days) history of febrile illness (rectal temperature ≥38.0°C),~6. Active untreated tuberculosis,~7. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems,~8. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,~9. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 3,~10. Any recent receipt of an inactivated or a live vaccine (≤ 30 days) or scheduled vaccination through visit 3

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Have Type 2 diabetes mellitus.~* Have a Body Mass Index within range 22 to 35kg/m2 inclusive.~* Females who meet above criteria must be physiologically incapable of becoming pregnant (i.e., surgically sterilized, or post-menopausal per protocol definition).~Exclusion criteria:~* Are currently taking insulin therapy.~* Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer).~* Have a history of stomach, liver, kidney, or other disease that with interfere with taking the study drug.~* Are currently using diuretics, oral or injectable corticosteroids (inhaled \& intranasal corticosteroids are permitted), or other medications that would cause you to deplete your fluid balance in your body; currently taking stable regimens for heart conditions; currently using prescription or non-prescription drugs within 7 days of starting the study that may interfere with the study drug.~* Would donate more than 450 ML of blood over a 2 month period.~* Physician does not think it is a good idea for you to participate in the trial. - Had a urinary tract infection or bladder infection in the last month. - Are currently drinking more than 2 beers, 1 glass of wine, or 1 glass of spirits daily.~* Have a positive urine drug screen test.~* Plan to change your smoking habits during the course of the trial.~* Have Hepatitis C, Hepatitis B, or HIV. - Have a lab or EKG abnormality. - High or low blood pressure.~* Have used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication.~* Are a male subject unwilling to abstain or use protection during intercourse.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of community acquired bacterial pneumonia (e.g. cough with purulent sputum or change in character of sputum consistent with bacterial infection, dyspnea or tachypnea, chest pain due to pneumonia, fever, presence of rales and/or signs of consolidation).~2. No prior systemic antibacterial therapy, unless failed other therapy.~3. Chest Xray shows new lobar or multilobar infiltrate(s) consistent with acute bacterial pneumonia.~4. PORT Risk Class II, III, or IV \<=105~5. Ability to take oral medication.~Exclusion Criteria:~1. Severe chronic obstructive pulmonary disease FEV1 \<30%.~2. Hospitalization within 90 days or residence in a long-term-care facility within 30 days prior to the onset of symptoms~3. Chemotherapy or radiation therapy within the previous 3 months.~4. Significant hepatic, hematological, renal abnormalities.~5. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g. life expectancy \<30 days).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levofloxacin (Type: ACTIVE_COMPARATOR): None
- CEM-101 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxyzine Dihydrochloride Premedication is a Necessity for Strabismus Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Strabismus, surgery needed~* Esotropia, surgery needed~Exclusion Criteria:~* Chronic disease~* Arrhythmia~* Glaucoma(narrow-angle)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: None): Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively.
- Midazolam&Hydroxyzine dihydrochloride1/2 (Type: None): Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively.
- Midazolam&Hydroxyzine dihydrochloride (Type: None): Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete